- Home
- NSP vs GERN Comparison
NSP vs GERN Comparison
Compare NSP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSP
- GERN
- Stock Information
- Founded
- NSP 1986
- GERN 1990
- Country
- NSP United States
- GERN United States
- Employees
- NSP N/A
- GERN N/A
- Industry
- NSP Professional Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NSP Consumer Discretionary
- GERN Health Care
- Exchange
- NSP Nasdaq
- GERN Nasdaq
- Market Cap
- NSP 2.9B
- GERN 2.5B
- IPO Year
- NSP 1997
- GERN 1996
- Fundamental
- Price
- NSP $76.76
- GERN $2.89
- Analyst Decision
- NSP Hold
- GERN Strong Buy
- Analyst Count
- NSP 4
- GERN 10
- Target Price
- NSP $95.67
- GERN $7.15
- AVG Volume (30 Days)
- NSP 391.8K
- GERN 14.8M
- Earning Date
- NSP 02-06-2025
- GERN 02-26-2025
- Dividend Yield
- NSP 3.12%
- GERN N/A
- EPS Growth
- NSP N/A
- GERN N/A
- EPS
- NSP 3.16
- GERN N/A
- Revenue
- NSP $6,547,871,000.00
- GERN $29,480,000.00
- Revenue This Year
- NSP $2.24
- GERN $31,478.06
- Revenue Next Year
- NSP $5.31
- GERN $290.89
- P/E Ratio
- NSP $24.33
- GERN N/A
- Revenue Growth
- NSP 2.38
- GERN 9199.68
- 52 Week Low
- NSP $71.69
- GERN $1.64
- 52 Week High
- NSP $117.48
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- NSP 46.90
- GERN 25.84
- Support Level
- NSP $73.60
- GERN $2.80
- Resistance Level
- NSP $79.38
- GERN $3.68
- Average True Range (ATR)
- NSP 2.54
- GERN 0.18
- MACD
- NSP 0.18
- GERN -0.04
- Stochastic Oscillator
- NSP 47.12
- GERN 10.23
About NSP Insperity Inc.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.